oncology bispecific antibody

  • Pancreatic Cancer Trial Ahead of Schedule, Gastric Cancer Fast Track Win

    Pancreatic Cancer Trial Ahead of Schedule, Gastric Cancer Fast Track Win

    A drug called givastomig produced a 77% response rate in gastric cancer. The stock trades 71% below its 52-week high. Sometimes the data and the price tell two different stories. AIM ImmunoTech Doses Final Patient in Phase 2 Pancreatic Cancer Trial Ahead of Schedule AIM ImmunoTech (NYSE American: AIM) had a busy stretch in the…

    read more